Patents Represented by Attorney Mehdi Ganjeizadeh
-
Patent number: 7244763Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: GrantFiled: February 6, 2004Date of Patent: July 17, 2007Assignee: Warner Lambert Company LLCInventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 7141606Abstract: The invention provides a new use of compounds for formula 1 or 1A or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of insomnia and related disorders.Type: GrantFiled: May 18, 2001Date of Patent: November 28, 2006Assignee: Warner-Lambert CompanyInventors: Justin Stephen Bryans, Leonard Theodore Meltzer
-
Patent number: 7067262Abstract: Described is a method for determining the binding ability of a compound to bind to an ?2?2 subunit of a calcium channel comprising: providing an ?2?2 subunit of a calcium channel, contacting the subunit with the compound, and determining the binding ability of the compound to bind to the subunit.Type: GrantFiled: May 8, 2001Date of Patent: June 27, 2006Assignee: Warner Lambert Company LLCInventor: Ti-Zhi Su
-
Patent number: 7030109Abstract: The present invention discloses radioligands of 9-arylsulfone of the formula (X) or a pharmaceutically acceptable salt or enantiomer thereof, which are useful in diagnosing depression, obesity and other CNS disorders.Type: GrantFiled: April 25, 2003Date of Patent: April 18, 2006Assignee: Pharmacia & Upjohn CompanyInventors: Eric Jon Jacobsen, Kalpana M. Merchant
-
Patent number: 7022694Abstract: The present invention provides compounds of Formula (I): wherein R1, R2, R3, R4, R5, R6 and --- have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods as well as processes and intermediates useful for preparing compounds of Formula (I). The compounds are useful as 5-HT ligands.Type: GrantFiled: July 11, 2002Date of Patent: April 4, 2006Assignee: Pharmacia & UpJohn CompanyInventors: Jian-Min Fu, Jeanette Kay Morris, Arthur Glenn Romero
-
Patent number: 6958218Abstract: A method for the screening of ligands which bind to soluble ?2?-1 subtype polypeptides.Type: GrantFiled: March 6, 2002Date of Patent: October 25, 2005Assignee: Warner-Lambert CompanyInventors: François Bertelli, Jason Peter Brown, Visaka Udeni Karalliadde Dissanayake, Nirmala Suman-Chauhan, Nicolas Steven Gee
-
Patent number: 6921835Abstract: The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.Type: GrantFiled: May 30, 2003Date of Patent: July 26, 2005Assignee: Warner Lambert CompanyInventors: Justin Stephen Bryans, David Christopher Horwell, Andrew John Thorpe, David Juergen Wustrow, Po-Wai Yuen
-
Patent number: 6872856Abstract: A method is provided for making an enantiomerically pure compound of the formula: in which R and R? represent C1?C10 alkyl, C2?C10 alkenyl or C3?C10 cycloalkyl and the wedges signify (S)- or (R)-stereochemistry, the substituents in compound (II) being trans. Conjugate addition is carried out between an organometallic nucleophile that provides a group R as defined above and (R)-4-acetoxycyclopent-2-en-1-one, (S)-4-acetoxycyclopent-2-en-1-one or a similar compound in which acetoxy is replaced by another leaving group to give, e.g.Type: GrantFiled: June 28, 2001Date of Patent: March 29, 2005Assignee: Warner-Lambert CompanyInventors: David Clive Blakemore, Justin Stephen Bryans
-
Patent number: 6833385Abstract: The invention is a novel series of compounds which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.Type: GrantFiled: December 19, 2003Date of Patent: December 21, 2004Assignee: Warner-Lambert CompanyInventor: Po-Wai Yuen
-
Patent number: 6828341Abstract: Described are cyclohexylamine derivatives of Formula I and pharmaceutically acceptable salts thereof, wherein R1, g, *, R, V, B, E, Y, G, H, X1, and d are as defined in the description. The compounds of Formulas I, VI, and VIa are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, trauma, hypoglycemia, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.Type: GrantFiled: March 27, 2002Date of Patent: December 7, 2004Assignee: Warner-Lambert CompanyInventors: Russell Joseph DeOrazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer
-
Patent number: 6794402Abstract: Described are bicycle-substituted cyclohexylamines of Formula I and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are defined in the specification.Type: GrantFiled: November 12, 2002Date of Patent: September 21, 2004Assignee: Warner-Lambert CompanyInventors: Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
-
Patent number: 6765022Abstract: Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are described in the specification.Type: GrantFiled: December 2, 2002Date of Patent: July 20, 2004Assignee: Warner-Lambert CompanyInventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
-
Patent number: 6710190Abstract: The invention is a novel series of compounds which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.Type: GrantFiled: November 21, 2001Date of Patent: March 23, 2004Assignee: Warner-Lambert CompanyInventor: Po-Wai Yuen
-
Patent number: 6642398Abstract: The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.Type: GrantFiled: December 20, 2002Date of Patent: November 4, 2003Assignee: Warner-Lambert CompanyInventors: Thomas Richard Belliotti, Justin Stephen Bryans, Ihoezo Victor Ekhato, Augustine Tobi Osuma, Robert Michael Schelkun, Jacob Bradley Schwarz, Andrew John Thorpe, Lawrence David Wise, David Juergen Wustrow, Po-Wai Yuen
-
Patent number: 6635673Abstract: The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.Type: GrantFiled: February 8, 2000Date of Patent: October 21, 2003Assignee: Warner-Lambert CompanyInventors: Justin Stephen Bryans, David Christopher Horwell, Andrew John Thorpe, David Juergen Wustrow, Po-Wai Yuen
-
Patent number: 6410536Abstract: This invention discloses quinoxalinones which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: August 3, 2000Date of Patent: June 25, 2002Assignee: Warner-Lambert CompanyInventors: Danette Andrea Dudley, Jeremy John Edmunds
-
Patent number: 6368815Abstract: An assay for the screening of a candiadte molecule that inhibits the expression or the activity of a human phosphodiesterase 4A (PDE4A) is disclosed. The method comprises incubating non-recombinant cells in the presence of a concentration of a phorbol ester sufficient to significantly increase PDE4A production in the cells. Next, a candidate molecule is added to the culture medium in which the phorbol ester-treated cells are cultured, then the cells are disrupted and harvested to produce a cell lysate. Finally, the cAMP content in the cell lysate is quantified and then the cAMP content in the cell lysate is compared to the cCAMP content in the cell lysate of the phorbol ester treated cells cultured in the absence of the candidate molecule.Type: GrantFiled: March 20, 2000Date of Patent: April 9, 2002Assignee: Warner-Lambert CompanyInventor: Corinne Szilagyi